1. Medtech Insight
  2. >>Market Intelligence
  3. >>Company Rankings

The Medtech 100 Ranking: A Successful Year But Industry Must Tread Carefully In 2023

From Medtronic to Horiba – the medtech industry’s leading companies by revenues

 
• By Ashley Yeo

Medtech Insight’s just-published ranking of the leading global medtechs based on revenues reported for fiscal 2021 reveals a picture of an industry overwhelmingly in growth, despite – or in some cases because of – the persistent effects of the pandemic.

2023 Medtech 100
• Source: Shutterstock

Medtech Insight's Medtech 100 ranking of companies based on revenues reported for 2021 shows a largely stable and growing industry, in which almost three quarters of manufacturers exceeded a billion dollars in sales.

The ranking is published on Medtech Insight’s portal under the Data tab – Company Rankings 2023.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Company Rankings

MTI100 - Into 2025: Investor Optimism Ahead As Big Medtech Proves ‘It’s All About Value’

 
• By Ashley Yeo

Pressure to exploit connected care functionality is accelerating the shift in care delivery away from the inpatient setting. Medtechs are reshaping to maximize faster-growth opportunities.

MTI100 - Medtech Industry Reaches New Chapter In Its Structural Evolution

The Top 100 ranking of global medtechs by revenues for 2023 illustrated how the leaders continue to tailor innovation to users and patients according to market trends while driving portfolio management for growth.

Medtech Insight’s Latest Medtech 100 Ranking Published

 
• By Ashley Yeo

Top 100 publicly listed medtech companies ranked by global revenues, and listings for the top cardiology, orthopedic, IVD and imaging performers based on 2023 or 2023-24 revenues, are now available from Medtech Insight.

More from Market Intelligence

Prostate Cancer Research Urges UK To Implement Screening Program Without Delay

 
• By Natasha Barrow

Implementing a reflex test alongside traditional prostate cancer screening is cost-effective for high-risk groups, claims Prostate Cancer Research. Oxford BioDynamics sheds light on UK market conditions influencing the adoption of its reflex test, EpiSwitch PSE.

Philips Partners With Three Health Insurance Providers To Remotely Monitor High-Risk Pregnancies

 
• By Natasha Barrow

Several counties in the US state of Georgia are maternity care “deserts.” Remote monitoring of high-risk pregnancies with maternal hypertension and diabetes could help improve the state’s high rate of maternal mortality, according to leading health service provider Philips.

Medtronic Widens Parkinson’s aDBS Opportunity With Key US Approvals

 
• By Natasha Barrow

Medtronic’s US FDA approval for BrainSense aDBS and BrainSense EI software features of the Percept neurostimulator device has quickly followed CE marking in January.